NeuroMetrix NURO 深 沪
已收盘 05-01 16:00:00 美东时间
4.58
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 4.58
- 总市值 943.34万
- 52周最高 4.73
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 2.66
- 委 比 0.00%
- 总股本 205.97万
- 历史最高 10880.00
- 量 比 0
- 振 幅 0.00%
- 历史最低 2.66
- 每 手 1
- 风险率 0.27%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Neuronetics to Present at the Canaccord Genuity 45th Annual Growth Conference
Neuronetics, Inc. announced that its CEO, Keith Sullivan, will present at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025. The presentation will be available to attendees for 14 days post-event. Neuronetics specializes in neurohealth therapies, with NeuroStar Advanced Therapy as its flagship product, offering non-drug treatment for mental health conditions. Its Greenbrook centers have delivered over 7.4 million treatments f...
08-04 20:30
NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results on Thursday, August 14 at 8:30 a.m. Eastern Time
NeuroOne Medical Technologies Corporation will release its Q3 2025 financial results on August 14, 2025, before market open. A conference call and webcast will be held at 8:30 a.m. Eastern time on the same day to discuss the results. Participants can join via phone or webcast using the provided details. A replay will be available until August 28, 2025. The company specializes in minimally invasive and high-definition solutions for neurological di...
07-31 12:30
NeuroOne® Receives Notice of Allowance for Key Patent from U.S. Patent & Trademark Office
NeuroOne Medical Technologies Corporation has received a notice of allowance for a strategic U.S. patent application focused on novel methods for making neural probe devices. This patent covers electrode material deposition, enhancing the functionality and profile of their electrodes. With this addition, their portfolio includes 17 issued and pending patents on thin-film electrode technologies. The Company aims to advance its technology platform ...
07-23 12:30
NeuroPace Announces Strategic CFO Transition
NeuroPace, Inc. appoints Patrick F. Williams as Chief Financial Officer, replacing Rebecca Kuhn, who will transition to an advisory role. Williams, with over 25 years of experience in medical device companies, brings expertise in scaling and growth. He will help expand access to the RNS System, a brain-responsive therapy for epilepsy patients. NeuroPace aims to enhance patient outcomes and advance its mission with Williams' leadership.
06-24 20:05
NeuroOne® Patient Surpasses One Year Milestone of Seizure Freedom Following Treatment with OneRF® Ablation System
NeuroOne Medical Technologies announced that Clara, a patient treated with their OneRF® Ablation System, has remained seizure-free for over a year. Clara, who previously experienced up to 10 seizures daily, has seen a significant improvement in her quality of life since the procedure in June 2024. The OneRF® System, which is FDA-cleared, uses the same sEEG electrode for both diagnosis and therapy, allowing ablation to be performed at the patient’...
06-23 12:30
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neuronetics, Inc. announced the granting of inducement awards, including PRSUs and RSUs, to Jeff Jones, a new non-executive employee. The PRSU awards are tied to achieving cash flow breakeven in specific fiscal quarters, with different vesting schedules based on performance. The RSUs will vest in three equal installments over three years. Neuronetics focuses on neurohealth treatments, offering non-drug therapies and SPRAVATO® for depression.
06-19 23:00
NeuroPace Secures Up to $75 Million in Debt Financing
NeuroPace, Inc. has secured a new $75 million credit facility with MidCap Financial, comprising a $60 million term loan and a $15 million revolving credit facility. The funds were used to repay an existing loan and support business growth, including expanding access to its RNS® System and pursuing new initiatives. The deal provides favorable terms and financial flexibility for the company's epileptic patients and strategic investments.
06-04 20:09
NeuroOne Strengthens Leadership Team with Appointment of Emily Johns as General Counsel and Corporate Secretary
NeuroOne Medical Technologies Corporation has appointed Emily Johns as General Counsel and Corporate Secretary. Dave Rosa, CEO, highlights her legal expertise and experience in fast-growing organizations, noting this hire will also help reduce legal costs. Johns, an experienced public company lawyer, joins after representing NeuroOne since 2017. She received an option to purchase 500,000 shares, with vesting over four years. NeuroOne, a medical t...
06-03 12:30
ElectroCore anticipates $30M 2025 revenue amid product line expansion
Earnings Call Insights: electroCore (ECOR) Q1 2025 Management View CEO Dan Goldberger emphasized the company's transformation into a broader bioelectronic technology entity, highlighting the recent ac...
05-08 11:18
170个员工，卖了218亿
本文来自格隆汇专栏：投中网；作者：张雪 OpenAI悟了，开始贯彻“突出应用导向”。 据知情人士透露，OpenAI正在洽谈以约30亿美元（约218.6亿人民币...
05-03 17:23
